Nomenclature: sst2 receptor

Family: Somatostatin receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates. 

Contents

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 369 17q24 SSTR2 somatostatin receptor 2 154-155
Mouse 7 369 11 E2 Sstr2 somatostatin receptor 2 144,154
Rat 7 369 10q32.1 Sstr2 somatostatin receptor 2 70
Previous and Unofficial Names
SSTR2
SRIF1
SRIF1A
Smstr2
SRIF-1
SS-2-R
SS2-R
SS2R
somatostatin receptor 2
somatostatin receptor subtype 2
somatostatin receptor type 2
somatotropin release-inhibiting factor receptor
SSTR-2
sst2
Smstr-2
Database Links
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
GPCRDB
GeneCards
GenitoUrinary Development Molecular Anatomy Project
HomoloGene
Human Protein Reference Database
InterPro
KEGG Gene
OMIM
PharmGKB Gene
PhosphoSitePlus
Protein Ontology (PRO)
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniGene Hs.
UniProtKB
Wikipedia
Natural/Endogenous Ligands
CST-14 {Sp: Mouse, Rat}
CST-17 {Sp: Human}
SRIF-14 {Sp: Human, Mouse, Rat}
SRIF-28 {Sp: Human, Mouse, Rat}
Comments: SRIF-14 and SRIF-28 are the active fragments of precursor somatostatin
Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[125I]LTT-SRIF-28 Hs Full agonist 9.9 – 10.0 pKd 124,129-130
pKd 9.9 – 10.0 [124,129-130]
[125I]Tyr3 SMS 201-995 Hs Full agonist 9.9 pKd 130-131
pKd 9.9 (Kd 1.3x10-10 M) [130-131]
[125I]CGP 23996 Hs Full agonist 9.8 pKd 130-131
pKd 9.8 [130-131]
[125I]MK-678 Mm Full agonist 9.6 pKd 105
pKd 9.6 [105]
[125I]Tyr3 SMS 201-995 Rn Full agonist 9.54 pKd 108
pKd 9.54 (Kd 2.9x10-10 M) [108]
[125I]Tyr10-CST14 Hs Full agonist 9.4 pKd 129,131
pKd 9.4 [129,131]
[125I]Tyr11-SRIF-14 Mm Full agonist 9.2 pKd 83
pKd 9.2 [83]
[125I]LTT-SRIF-28 Rn Full agonist 9.02 – 9.34 pKd 117-118
pKd 9.02 – 9.34 (Kd 9.5x10-10 – 4.6x10-10 M) [117-118]
[125I]Tyr11-SRIF-14 Rn Full agonist 8.96 pKd 117
pKd 8.96 (Kd 1.09x10-9 M) [117]
L-054,522 Hs Full agonist 11.0 pKi 156
pKi 11.0 [156]
NC 8-12 Hs Full agonist 10.6 pKi 101
pKi 10.6 [101]
EC 5-21 Hs Full agonist 10.6 pKi 101
pKi 10.6 [101]
L-779,976 Hs Full agonist 10.3 pKi 124
pKi 10.3 [124]
SRIF-14 {Sp: Human, Mouse, Rat} Hs Full agonist 8.9 – 10.5 pKi 23,45,101,104,124,129-131,156
pKi 8.9 – 10.5 [23,45,101,104,124,129-131,156]
DC 23-60 Hs Full agonist 9.6 pKi 101
pKi 9.6 [101]
MK-678 Hs Full agonist 8.8 – 10.3 pKi 23,101,129-131,156
pKi 8.8 – 10.3 [23,101,129-131,156]
BIM 23059 Hs Full agonist 9.4 pKi 101
pKi 9.4 [101]
BIM 23023 Hs Full agonist 9.4 pKi 101
pKi 9.4 [101]
MK-678 Rn Full agonist 9.3 pKi 92
pKi 9.3 [92]
L-363,377 Hs Full agonist 9.3 pKi 124,156
pKi 9.3 [124,156]
SRIF-28 {Sp: Human, Mouse, Rat} Hs Full agonist 8.4 – 10.2 pKi 23,45,101,129-131
pKi 8.4 – 10.2 [23,45,101,129-131]
octreotide Hs Full agonist 8.7 – 9.9 pKi 23,101,129-131,156
pKi 8.7 – 9.9 [23,101,129-131,156]
vapreotide Hs Full agonist 8.3 – 10.1 pKi 23,101
pKi 8.3 – 10.1 [23,101]
SRIF-14 {Sp: Human, Mouse, Rat} Mm Full agonist 8.8 – 9.6 pKi 92
pKi 8.8 – 9.6 [92]
BIM 23060 Hs Full agonist 9.2 pKi 101
pKi 9.2 [101]
BIM 23023 Rn Full agonist 9.2 pKi 92
pKi 9.2 [92]
lanreotide Hs Full agonist 8.7 – 9.6 pKi 23,101,129-131
pKi 8.7 – 9.6 [23,101,129-131]
vapreotide Rn Full agonist 9.1 pKi 92
pKi 9.1 [92]
CST-17 {Sp: Human} Hs Full agonist 8.8 – 9.3 pKi 45,129,131
pKi 8.8 – 9.3 [45,129,131]
CGP 23996 Hs Full agonist 8.6 – 9.1 pKi 23,129-131
pKi 8.6 – 9.1 [23,129-131]
SRIF-14 {Sp: Human, Mouse, Rat} Rn Full agonist 8.8 pKi 92
pKi 8.8 [92]
BIM 23068 Hs Full agonist 8.8 pKi 101
pKi 8.8 [101]
SRIF-28 {Sp: Human, Mouse, Rat} Rn Full agonist 8.8 pKi 92
pKi 8.8 [92]
lanreotide Rn Full agonist 8.8 pKi 92
pKi 8.8 [92]
CST-14 {Sp: Mouse, Rat} Hs Full agonist 8.4 – 9.0 pKi 129-131
pKi 8.4 – 9.0 [129-131]
octreotide Rn Full agonist 8.7 pKi 92
pKi 8.7 [92]
BIM 23034 Hs Full agonist 8.6 pKi 101
pKi 8.6 [101]
L-362,855 Hs Full agonist 8.4 – 8.8 pKi 129-131
pKi 8.4 – 8.8 [129-131]
MK-678 Mm Full agonist 7.1 – 9.9 pKi 92
pKi 7.1 – 9.9 [92]
BIM 23052 Hs Full agonist 8.1 – 8.8 pKi 23,129-131
pKi 8.1 – 8.8 [23,129-131]
L-363,301 Hs Full agonist 8.3 – 8.5 pKi 129,131
pKi 8.3 – 8.5 [129,131]
NC 4-28B Hs Full agonist 8.4 pKi 101
pKi 8.4 [101]
octreotide Mm Full agonist 7.5 – 9.2 pKi 92
pKi 7.5 – 9.2 [92]
BIM 23023 Mm Full agonist 7.0 – 9.4 pKi 92
pKi 7.0 – 9.4 [92]
lanreotide Mm Full agonist 6.9 – 9.1 pKi 92
pKi 6.9 – 9.1 [92]
L-362,855 Rn Full agonist 7.9 pKi 92
pKi 7.9 [92]
BIM 23030 Hs Full agonist 7.7 – 7.9 pKi 129-131
pKi 7.7 – 7.9 [129-131]
L-362,855 Mm Full agonist 7.0 – 8.5 pKi 92
pKi 7.0 – 8.5 [92]
vapreotide Mm Full agonist 6.1 – 9.2 pKi 92
pKi 6.1 – 9.2 [92]
BIM 23056 Hs Full agonist 6.2 – 6.7 pKi 23,129-131
pKi 6.2 – 6.7 [23,129-131]
L-779,976 Rn Agonist 10.05 pEC50 86
pEC50 10.05 (EC50 9x10-11 M) [86]
L-779,976 Rn Partial agonist 9.25 pEC50 86
pEC50 9.25 (EC50 5.6x10-10 M) [86]
KE 108 Rn Agonist 7.92 – 10.24 pEC50 33,67
pEC50 7.92 – 10.24 (EC50 1.21x10-8 – 5.7x10-11 M) [33,67]
SRIF-14 {Sp: Human, Mouse, Rat} Rn Agonist 9.14 – 8.99 pEC50 86
pEC50 9.14 – 8.99 (EC50 7.3x10-10 – 1.02x10-9 M) [86]
pasireotide Rn Agonist 7.76 – 9.07 pEC50 33,67
pEC50 7.76 – 9.07 (EC50 1.75x10-8 – 8.6x10-10 M) [33,67]
KE 108 Rn Partial agonist 7.63 pEC50 67
pEC50 7.63 (EC50 2.36x10-8 M) [67]
pasireotide Rn Partial agonist 7.63 pEC50 67
pEC50 7.63 (EC50 2.33x10-8 M) [67]
L-363,409 Mm Full agonist 12.0 pIC50 83
pIC50 12.0 [83]
BIM 23034 Mm Full agonist 11.7 pIC50 105
pIC50 11.7 [105]
BIM 23059 Mm Full agonist 11.1 pIC50 105
pIC50 11.1 [105]
BIM 23027 Mm Full agonist 10.2 – 12.0 pIC50 83,105
pIC50 10.2 – 12.0 [83,105]
BIM 23060 Mm Full agonist 10.9 pIC50 105
pIC50 10.9 [105]
NC 4-28B Mm Full agonist 10.0 – 11.7 pIC50 83,105
pIC50 10.0 – 11.7 [83,105]
BIM 23027 Hs Agonist 10.85 pIC50 28
pIC50 10.85 (IC50 1.4x10-11 M) [28]
BIM 23068 Mm Full agonist 9.8 pIC50 105
pIC50 9.8 [105]
[125I]BIM23027 Rn Full agonist 9.7 pIC50 64
pIC50 9.7 (IC50 2.2x10-10 M) [64]
BIM 23197 Hs Full agonist 9.7 pIC50 127
pIC50 9.7 [127]
[Ga-DOTA,Tyr3,Thr8]octreotide Hs Full agonist 9.7 pIC50 7,119
pIC50 9.7 (IC50 2x10-10 M) [7,119]
BIM 23027 Rn Agonist 9.7 pIC50 64
pIC50 9.7 (IC50 2x10-10 M) [64]
NC 8-12 Mm Full agonist 9.5 pIC50 83
pIC50 9.5 [83]
L-363,377 Mm Full agonist 9.4 pIC50 83
pIC50 9.4 [83]
[125I][Tyr3,Thr8]octreotide Hs Full agonist 9.33 pIC50 150
pIC50 9.33 (IC50 4.7x10-10 M) [150]
SRIF-28 {Sp: Human, Mouse, Rat} Mm Full agonist 9.0 – 9.5 pIC50 92
pIC50 9.0 – 9.5 [92]
BOC-ATE Hs Full agonist 9.1 pIC50 54
pIC50 9.1 [54]
maltotriose-[125I][Tyr3,Thr8]octreotide Hs Full agonist 9.02 pIC50 150
pIC50 9.02 (IC50 9.5x10-10 M) [150]
KE 108 Hs Full agonist 9.0 pIC50 110
pIC50 9.0 [110]
DC 23-60 Mm Full agonist 9.0 pIC50 105
pIC50 9.0 [105]
pasireotide Hs Full agonist 9.0 pIC50 126
pIC50 9.0 [126]
[125I]Tyr3 SMS 201-995 Hs Full agonist 8.89 pIC50 150
pIC50 8.89 (IC50 1.3x10-9 M) [150]
[111In]DOTA-BOC-ATE Hs Full agonist 8.8 pIC50 54
pIC50 8.8 [54]
In-NODAGATOC Hs Full agonist 8.77 pIC50 43
pIC50 8.77 (IC50 1.7x10-9 M) [43]
Ga-DOTA-NOC Hs Full agonist 8.72 pIC50 7
pIC50 8.72 (IC50 1.9x10-9 M) [7]
[111In]DOTA-NOC-ATE Hs Full agonist 8.7 pIC50 54
pIC50 8.7 [54]
AM3 Hs Full agonist 8.64 pIC50 48
pIC50 8.64 (IC50 2.3x10-9 M) [48]
L-363,301 Mm Full agonist 8.1 – 9.1 pIC50 83,105
pIC50 8.1 – 9.1 [83,105]
Ga-DOTA-TOC Hs Full agonist 8.6 pIC50 119
pIC50 8.6 (IC50 2.5x10-9 M) [119]
BIM 23066 Mm Full agonist 8.5 pIC50 105
pIC50 8.5 [105]
[111In]DOTA-NOC Hs Full agonist 8.5 pIC50 151
pIC50 8.5 [151]
demotate 2 Hs Full agonist 8.49 pIC50 89
pIC50 8.49 (IC50 3.2x10-9 M) [89]
NODAGA-[Tyr3]-octreotide Hs Full agonist 8.49 pIC50 43
pIC50 8.49 (IC50 3.2x10-9 M) [43]
SiFA-Asn(AcNH-β-Glc)-PEG-Tyr³-octreotate Hs Full agonist 8.48 pIC50 153
pIC50 8.48 (IC50 3.3x10-9 M) [153]
[67Ga]NODAGA-[Tyr3]octreotide Hs Full agonist 8.46 pIC50 43
pIC50 8.46 (IC50 3.5x10-9 M) [43]
NOC-ATE Hs Full agonist 8.4 pIC50 54
pIC50 8.4 [54]
[111In,90Y]DOTA-NOC Hs Full agonist 8.4 pIC50 151
pIC50 8.4 [151]
Ga-KE88 Hs Full agonist 8.39 pIC50 55
pIC50 8.39 (IC50 4.1x10-9 M) [55]
SiFA-Asn(AcNH-β-Glc)-Tyr³-octreotate Hs Full agonist 8.36 pIC50 153
pIC50 8.36 (IC50 4.4x10-9 M) [153]
EC 5-21 Mm Full agonist 8.3 pIC50 105
pIC50 8.3 [105]
BIM 23030 Mm Full agonist 8.2 pIC50 105
pIC50 8.2 [105]
Y-KE88 Hs Full agonist 8.0 pIC50 55
pIC50 8.0 (IC50 9.9x10-9 M) [55]
[111In,90Y]DOTA-TOC Hs Full agonist 7.9 pIC50 151
pIC50 7.9 [151]
[111In,90Y]DOTA-OC Hs Full agonist 7.7 pIC50 151
pIC50 7.7 [151]
[111In,90Y]DOTA-LAN Hs Full agonist 7.6 pIC50 151
pIC50 7.6 [151]
View species-specific agonist tables
Agonist Comments
Liu et al (2005) [160] describe L-779,976 as a full agonist in its ability to inhibit cAMP accumulation, whereas at high concentration it acts as a partial agonist of receptor internalisation (endocytosis). Similarly, SOM-230 and KE 108 have been reported to act as full or partial agonists depending on which outcome of receptor occupation is measured [33,67]. Both ligands exhibit biased agonism: they activate and antagonise distinct signalling pathways [33]. Although SOM-230 and KE 108 potently inhibited cAMP accumulation in sst2A expressing HEK cells, as would be expected of a somatostatin analog, these compounds were also able to antagonise somatostatin induced increase in intracellular calcium and behaved as partial agonists/antagonists for ERK phosphorylation [33].
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[D-Tyr8]CYN 154806 Hs Antagonist 8.1 – 8.9 pKd 99
pKd 8.1 – 8.9 [99]
BASS antagonist Hs Antagonist 9.52 pKi 14
pKi 9.52 (Ki 3x10-10 M) [14]
[L-Tyr8]CYN 154806 Hs Antagonist 8.1 – 8.4 pKi 99
pKi 8.1 – 8.4 [99]
PRL-2915 Rn Antagonist 7.9 pKi 63
pKi 7.9 [63]
PRL-2970 Rn Antagonist 7.6 pKi 63
pKi 7.6 [63]
AC-178,335 Rn Antagonist 6.8 pKi 15
pKi 6.8 [15]
KE 108 Rn Antagonist <5.0 pEC50 33
pEC50 <5.0 (EC50 >1x10-5 M) [33]
pasireotide Rn Antagonist <5.0 pEC50 33
pEC50 <5.0 (EC50 >1x10-5 M) [33]
analog 31 Hs Antagonist 9.15 pIC50 32
pIC50 9.15 (IC50 7x10-10 M) [32]
analog 3 Hs Antagonist 9.12 pIC50 32
pIC50 9.12 (IC50 7.5x10-10 M) [32]
Ga-NODAGA-LM3 Hs Antagonist 8.89 pIC50 47
pIC50 8.89 (IC50 1.3x10-9 M) [47]
DOTA-BASS Hs Antagonist 8.82 pIC50 32
pIC50 8.82 (IC50 1.5x10-9 M) [32]
analog 30 Hs Antagonist 8.77 pIC50 32
pIC50 8.77 (IC50 1.7x10-9 M) [32]
BIM 23627 Hs Antagonist 8.2 pIC50 143
pIC50 8.2 [143]
BIM 23454 Hs Antagonist 7.5 pIC50 143
pIC50 7.5 [143]
View species-specific antagonist tables
Primary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family
G protein independent mechanism
G protein (identity unknown)
Adenylate cyclase inhibition
Potassium channel
Calcium channel
Other - See Comments
Comments:  G protein independent: Inhibition of phosphoinositide 3-kinase activity through direct molecular interactions (and competition) between sst2 first intracellular loop and the regulatory PI3K p85 subunit or filamin-A [19,97].
G-protein-dependent: activation of ERK and PI3K activity in sst2-transfected CHO cells [75] and [59].
Other: Inhibition of L and N voltage gated Ca2++ channels activity [157].
References:  65,68,79,128
Secondary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family
Gq/G11 family
G protein independent mechanism
G protein (identity unknown)
Adenylate cyclase stimulation
Phospholipase C stimulation
Potassium channel
Calcium channel
Phospholipase D stimulation
Other - See Comments
Comments:  PLC activation is via the Gq G-protein.
K+ channel activation and Ca2+ channel inhibition is via Gi/Go.
There is also protein tyrosine phosphatase (PTP) activation via a PTX-insensitive G-protein.
sst2 activates PLC via a mechanism involving Galpha14 and has also been shown to activate PLD in clonal beta cells HIT-T15 [35,62,84].
Adenylate cyclase stimulation has been reported at very high agonist doses in overexpression systems.
Other downstream events reported to be consequential to somatostatin binding include inhibition of the PI3K-mTOR pathway and cap-dependent translation [11,30,140], activation of the protein-tyrosine phosphatases SHP-1, SHP-2 or PTPeta [13,49] and inhibition of eNOS activity [8].
References:  4,8,11,13,24,30,35,40,49,62,72,79,84,106,139-140
Tissue Distribution
Pancreatic exocrine tissue and pancreatic ductal adenocarcinoma.
Species:  Human
Technique:  Immunohistochemistry, RT-PCR
References:  25,76,141
Peritumoral veins of human tumours.
Species:  Human
Technique:  Radioligand binding.
References:  41
Proliferating endothelium.
Species:  Human
Technique:  Immunocytochemistry.
References:  3
Pituitary.
Species:  Human
Technique:  RT-PCR.
References:  94
Kidney.
Species:  Human
Technique:  Autoradiography.
References:  112
Vessels.
Species:  Human
Technique:  Autoradiography.
References:  41,111,116
Pancreatic islets: co-localised with glucagon in alpha-cells.
Species:  Human
Technique:  immunocytochemistry.
References:  73
Brain.
Species:  Human
Technique:  Autoradiography.
References:  109
Lymphoid cells.
Species:  Human
Technique:  RT-PCR.
References:  142
A and B pancreatic islet cells, but not in adjacent acinar cells.
Species:  Human
Technique:  Immunohistochemistry, autoradiography
References:  114
Lymphoid tissue, plexus.
Species:  Human
Technique:  Immunohistochemistry, autoradiography.
References:  115
Lymphoid tissue.
Species:  Human
Technique:  Autoradiography, in vivo scintigraphy
References:  113,121
GI tract (gastrointestinal lymphatic and nervous components, but not in gastrointestinal circular and longitudinal smooth muscle).
Species:  Human
Technique:  Immunohistochemistry.
References:  57,115
Macrophages.
Species:  Human
Technique:  RT-PCR.
References:  9
Spleen.
Species:  Human
Technique:  Immunohistochemistry.
References:  50
Thymocytes.
Species:  Human
Technique:  RT-PCR.
References:  51
Parietal cells and ECL cells in stomach, and myenteric neurons.
Species:  Mouse
Technique:  Immunohistochemistry and LacZ knock-in.
References:  5
Cortex, amygdala, claustrum, endopiriform nucleus, arcuate and periventricular nuclei of the hypothalamus, medial habenular nucleus.
Species:  Mouse
Technique:  in situ hybridisation.
References:  20
High levels in the cerebrum and kidney. Low levels in the jejunum, colon and liver.
Species:  Mouse
Technique:  RNA blotting.
References:  154
Hypothalamus: Medial preoptic area, suprachiasmatic nucleus, arcuate nucleus, anterior hypothalamic nucleus, ventromedial and dorsomedial nuclei, medial tuberal nucleus.
Species:  Rat
Technique:  in situ hybridisation.
References:  16
Pancreas.
Species:  Rat
Technique:  Immunohistochemistry.
References:  66,136
Hippocampus and many other brain areas.
Species:  Rat
Technique:  Immunohistochemistry.
References:  42
Anterior pituitary.
Species:  Rat
Technique:  Immunohistochemistry.
References:  93
Aorta.
Species:  Rat
Technique:  RT-PCR and immunocytochemistry.
References:  69
Fundic gastric mucosa of the stomach.
Species:  Rat
Technique:  RT-PCR.
References:  80
Pituitary: somatotrophs (GH release), thyrotrophs (TSH release), lactotrophs (PRL release), as well as gonadotrophs and corticotrophs.
Species:  Rat
Technique:  double label in situ hybridisation.
References:  38
Pituitary.
Species:  Rat
Technique:  RT-PCR.
References:  38,46
Adrenal gland.
Species:  Rat
Technique:  Autoradiography.
References:  91
Pituitary, spleen and pancreas.
Species:  Rat
Technique:  Nuclease protection analysis.
References:  22
High levels in the amygdala, cortex, hypothalamus and hippocampus. Medium levels in the striatum, midbrain, thalamus, cerebellum and spinal cord.
Species:  Rat
Technique:  Nuclease protection analysis.
References:  22
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of GH release from rat anterior pituitary.
Species:  Rat
Tissue:  Rat anterior pituitary.
Response measured:  Inhibition of GH release.
References:  105
Measurement of CAMP accumulation in CHO cells stably transfected with human sst2 receptors.
Species:  Human
Tissue:  CHO cells expressing the luciferase reporter gene under the control of the serum response element, expressing recombinant human sst2 receptors.
Response measured:  Inhibition of cAMP accumulation.
References:  98
Measurement of agonist-driven luciferase expression in CHO cells stably transfected with human sst2 receptors.
Species:  Human
Tissue:  CHO cells expressing the luciferase reporter gene under the control of the serum response element, expressing recombinant sst2 receptors.
Response measured:  Inhibition of agonist-driven expression of the luciferase reporter gene.
References:  98
Measurement of PLC activity and cytosolic Ca2+ levels in COS-7 cells stably transfected with human sst2 receptors.
Species:  Human
Tissue:  COS-7 cells.
Response measured:  Activation of PLC and Ca2+ mobilisation.
References:  4
Measurement of the cAMP and Ca2+ levels in GC cells (growth cells) from a rat somatotroph tumour treated with the sst2 selective agonist L-779,976.
Species:  Rat
Tissue:  GC cells (growth cells) from a rat somatotroph tumour endogenously expressing all 5 SRIF receptors.
Response measured:  Inhibition of basal cAMP and Ca2+ levels.
References:  31
Measurement of GH release from GC cells (growth cells) from a rat somatotroph tumour treated with the sst2 selective agonist L-779,976.
Species:  Rat
Tissue:  GC cells (growth cells) from a rat somatotroph tumour endogenously expressing all 5 sst receptors.
Response measured:  Reduction in GH secretion.
References:  31
Measurement of GH release from primary cultures of rat anterior pituitary cells.